Milestone Pharmaceuticals Inc.
MIST · NASDAQ
Market closed$1.19$-0.055000 (-4.44%)After hours $1.22 · +2.95%
Key statistics
Previous close$1.24
Open$1.21
Day high$1.25
Day low$1.18
52-week high$3.06
52-week low$1.00
Market cap101.78M
Volume1.50M
Average volume1.35M
P/E ratio-1.74
Forward P/E—
EPS-0.68
Dividend yield0.00%
Market context
Why it moved
MIST shares declined amid a broad market sell-off driven by escalating U.S.-Iran military conflict threatening the Strait of Hormuz, rising oil prices, persistent AI-driven inflation concerns, and continued pressure on chip and technology stocks.
What is happening
Recent company-specific developments and publisher coverage.
Seeking Alpha · June 9, 2026Milestone Pharmaceuticals: Here Comes The Revenue Ramp (NASDAQ:MIST)PR Newswire · June 1, 2026Heart Rhythm Society and Milestone Pharmaceuticals Partner to Expand SVT Patient Education Through UpBeat.orgQuiver Quantitative · May 13, 2026Milestone Pharmaceuticals Reports Progress on CARDAMYST™ Launch and Financial Performance for Q1 2026Stock Titan · May 6, 2026Biotech Milestone pairs May 13 results with investor webcastTimothy Sykes · March 22, 2026Milestone Pharmaceuticals Faces Financial Challenges amidst Market ShiftsGlobeNewswire · January 26, 2026Milestone Pharmaceuticals Announces U.S. Availability ofSeeking Alpha · January 15, 2026Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense (MIST) Benzinga · May 14, 2026Wells Fargo Maintains Overweight on Milestone Pharmaceuticals, Lowers Price Target to $7 Mt Newswire · May 13, 2026Milestone Pharmaceuticals Files $300 Million Mixed Shelf Benzinga · May 13, 2026Milestone Pharmaceuticals May Offer Up To $100M Common Shares Via Cantor Fitzgerald Sales Agreement Benzinga · May 13, 2026Milestone Pharmaceuticals Files Prospectus To Offer Securities Up To $300M Benzinga · May 13, 2026Milestone Reports Q1 Results, Highlights Initial CARDAMYST Sales Benzinga · May 13, 2026Milestone Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript Benzinga · May 13, 2026Milestone Expands CARDAMYST Push Into Europe, China And New AFib Trial Mt Newswire · April 10, 2026Raymond James Initiates Milestone Pharmaceuticals at Strong Buy